AbbVie, a leading pharmaceutical company, has announced a significant investment of $195 million in its North Chicago, Illinois manufacturing plant. The expansion aims to boost domestic active pharmaceutical ingredient (API) production in the US and support innovation in the industry.
The new facility will enhance AbbVie’s chemical synthesis capabilities, enabling the production of current and next-generation neuroscience, immunology, and oncology medicines. This investment is part of the company’s broader commitment to invest over $10 billion in the US to expand critical manufacturing capabilities and capacity.
Construction on the new facility is set to begin in fall 2025, with the site expected to be fully operational by 2027. The expansion will not only boost American jobs but also bolster AbbVie’s presence in Illinois, where it is headquartered and employs over 11,000 people.
Governor JB Pritzker praised the investment, stating that it demonstrates Illinois’ world-class workforce, infrastructure, and research institutions. He added that the move bolsters the state’s biomanufacturing ecosystem and creates jobs while driving innovation in next-generation medicines.
This expansion is a testament to AbbVie’s commitment to developing innovative medicines and solutions that address serious health issues. The company aims to have a remarkable impact on people’s lives across various therapeutic areas, including immunology, oncology, neuroscience, and eye care.
Source: https://news.abbvie.com/2025-08-12-AbbVie-Announces-195-Million-Investment-to-Expand-Active-Pharmaceutical-Ingredient-Manufacturing-in-the-U-S